Evidence map›Paper›PMID 33992710›Full record

ArticleAntiviral research2021

New methylene blue derivatives suggest novel anti-orthopoxviral strategies.

Lalita Priyamvada, Jillybeth Burgado, Marissa Baker-Wagner, Anatoliy Kitaygorodskyy, Victoria Olson, Vishwanath R Lingappa, Panayampalli Subbian Satheshkumar

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antiviral research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. iScience · 2023
    Review
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lalita PriyamvadaPoxvirus and Rabies Branch, Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta, GA, 30329, USA.
Jillybeth BurgadoPoxvirus and Rabies Branch, Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta, GA, 30329, USA.
Marissa Baker-WagnerProsetta Biosciences, 670 5th Street, San Francisco, CA, 94107, USA.
Anatoliy KitaygorodskyyProsetta Biosciences, 670 5th Street, San Francisco, CA, 94107, USA.
Victoria OlsonPoxvirus and Rabies Branch, Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta, GA, 30329, USA.
Vishwanath R LingappaProsetta Biosciences, 670 5th Street, San Francisco, CA, 94107, USA. Electronic address: vlingappa@prosetta.com.
Panayampalli Subbian SatheshkumarPoxvirus and Rabies Branch, Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta, GA, 30329, USA. Electronic address: xdv3@cdc.gov.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Decades after the eradication of smallpox and the discontinuation of routine smallpox vaccination, over half of the world's population is immunologically naïve to variola virus and other orthopoxviruses (OPXVs). Even in those previously vaccinated against smallpox, protective immunity wanes over time. As such, there is a concomitant increase in the incidence of human OPXV infections worldwide. To identify novel antiviral compounds with potent anti-OPXV potential, we characterized the inhibitory activity of PAV-866 and other methylene blue derivatives against the prototypic poxvirus, vaccinia virus (VACV). These compounds inactivated virions prior to infection and consequently inhibited viral binding, fusion and entry. The compounds exhibited strong virucidal activity at non-cytotoxic concentrations, and inhibited VACV infection when added before, during or after viral adsorption. The compounds were effective against other OPXVs including monkeypox virus, cowpox virus and the newly identified Akhmeta virus. Altogether, these findings reveal a novel mode of inhibition that has not previously been demonstrated for small molecule compounds against VACV. Additional studies are in progress to determine the in vivo efficacy of these compounds against OPXVs and further characterize the anti-viral effects of these derivatives.

Indexed as

Antiviral AgentsCell LineCowpox virusHeLa CellsHumansMethylene BlueMonkeypox virusOrthopoxvirusVaccinia virusVirus AttachmentAntiviral AgentsMethylene BlueAntiviralMethylene blueNovel inhibitorPAV-866PoxvirusesVaccinia virus

Identifiers

PMID33992710
PMCPMC9629033

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.